Details of the Drug

General Information of Drug (ID: DMF8Y74)

Drug Name
Hydroxyzine
Synonyms
Atara; Atarax; Ataraxoid; Atarazoid; Atarox; Atazina; Aterax; Deinait; Durrax; Hidroxizina; Hychotine; Hydroksyzyny; Hydroxine; Hydroxizine; Hydroxizinum; Hydroxycine; Hydroxyzin; Hydroxyzinum; Hydroxyzyne; Idrossizina; Neurozina; Nevrolaks; Orgatrax; Pamazone; Parenteral; Paxistil; Placidol; Plaxidol; Tranquizine; Traquizine; Vistaril; Atarax base; Hydroksyzyny [Polish]; Hydroxyzine Hcl; Hydroxyzine base; Hydroxyzine hydrochloride; Idrossizina [DCIT]; NP 212; UCB 4492; UCB 492; Atarax (TN); Hidroxizina [INN-Spanish]; Hy-Pam 25; Hydroxyzine (INN); Hydroxyzine [INN:BAN]; Hydroxyzinum [INN-Latin]; Marex (TN); Neo-Calma; Tran-Q; U.CB 4492; Vesparaz-Wirkstoff; Vistaril (TN); U.C.B 4492; N-(4-Chlorobenzhydryl)-N'-(hydroxyethoxyethyl)piperazine; N-(4-Chlorobenzhydryl)-N'-(hydroxyethyloxyethyl)piperazine; Ethanol, 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-(9CI); 1-(p-Chloro-.alpha.-phenylbenzyl)-4-[2-[(2-hydroxyethoxy)ethyl]piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(2-hydroxyethoxyethyl)piperazine; 1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)diethylenediamine; 1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)ethyl]diethylenediamine; 1-(p-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)ethyl]piperazine; 1-(p-Chlorodiphenylmethyl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine; 1-(p-Chlorodiphenylmethyl)-4-[2-(2-hydroxyethoxy)ethyl]piperazine; 2-(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)ethanol; 2-(2-(4-(p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)ethanol; 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethanol; 2-[(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]ethanol; 2-[2-[4-(p-Chloro-.alpha.-phenylbenzyl)-1-piperazinyl]ethoxy]ethanol; 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol
Indication
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [1]
Anxiety disorder 6B00-6B0Z Approved [2]
Urticaria EB00-EB05 Approved [1]
Pruritus EC90 Investigative [1]
Therapeutic Class
Hypnotics and Sedatives
Affected Organisms
Humans and other mammals
ATC Code
N05BB01: Hydroxyzine
N05BB: Diphenylmethane derivatives
N05B: ANXIOLYTICS
N05: PSYCHOLEPTICS
N: NERVOUS SYSTEM
N05BB01: Hydroxyzine
N05BB: Diphenylmethane derivatives
N05B: ANXIOLYTICS
N05: PSYCHOLEPTICS
N: NERVOUS SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 374.9
Logarithm of the Partition Coefficient (xlogp) 3.7
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 2600 mcg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 3-5 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 76% [3]
Clearance
The clearance of drug is 31.1 +/- 11.1 mL/min/kg [5]
Elimination
Approximately 70% of hydroxyzine's active metabolite, cetirizine, is excreted unchanged in the urine [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 14 - 25 hours [7]
Metabolism
The drug is metabolized via the liver [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 15.2418 micromolar/kg/day [8]
Vd
The volume of distribution (Vd) of drug is 16.0 +/- 3.0 L/kg [7]
Water Solubility
The ability of drug to dissolve in water is measured as 700 mg/mL [4]
Chemical Identifiers
Formula
C21H27ClN2O2
IUPAC Name
2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol
Canonical SMILES
C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
InChI
InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2
InChIKey
ZQDWXGKKHFNSQK-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3658
ChEBI ID
CHEBI:5818
CAS Number
68-88-2
UNII
30S50YM8OG
DrugBank ID
DB00557
TTD ID
D0O6SX
INTEDE ID
DR0840
ACDINA ID
D00318
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Antagonist [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 3A5 (CYP3A5)
Main DME 		DEIBDNY CP3A5_HUMAN Substrate [10]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Gene/Protein Processing [11]
Antileukoproteinase (SLPI) OTUNFUU8 SLPI_HUMAN Gene/Protein Processing [12]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Gene/Protein Processing [12]
Interleukin-24 (IL24) OT4VUWH1 IL24_HUMAN Gene/Protein Processing [12]
Phosphatidylcholine translocator ABCB4 (ABCB4) OTE6PY83 MDR3_HUMAN Gene/Protein Processing [13]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Gene/Protein Processing [9]
PTB-containing, cubilin and LRP1-interacting protein (PID1) OT5YJ7FI PCLI1_HUMAN Gene/Protein Processing [12]
Transmembrane protease serine 2 (TMPRSS2) OTN44YQ5 TMPS2_HUMAN Gene/Protein Processing [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Allergic rhinitis
ICD Disease Classification CA08.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histamine H1 receptor (H1R) DTT HRH1 6.74E-01 0.13 0.43
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 9.57E-01 9.43E-03 1.29E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.76E-01 1.26E-01 8.27E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Hydroxyzine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Ivosidenib. Acute myeloid leukaemia [2A60] [14]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Midostaurin. Acute myeloid leukaemia [2A60] [15]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Idarubicin. Acute myeloid leukaemia [2A60] [15]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Daunorubicin. Acute myeloid leukaemia [2A60] [15]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Arn-509. Acute myeloid leukaemia [2A60] [16]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Gilteritinib. Acute myeloid leukaemia [2A60] [17]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Hydroxyzine and Oliceridine. Acute pain [MG31] [18]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Scopolamine. Addictive disorder [6C50-6C5Z] [19]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [20]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [20]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [19]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Memantine. Alzheimer disease [8A20] [19]
Galantamine DMEO794 Moderate Antagonize the effect of Hydroxyzine when combined with Galantamine. Alzheimer disease [8A20] [21]
Rivastigmine DMG629M Moderate Antagonize the effect of Hydroxyzine when combined with Rivastigmine. Alzheimer disease [8A20] [21]
Donepezil DMIYG7Z Moderate Antagonize the effect of Hydroxyzine when combined with Donepezil. Alzheimer disease [8A20] [21]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Hydroxyzine and Metronidazole. Amoebiasis [1A36] [22]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Ivabradine. Angina pectoris [BA40] [16]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Dronedarone. Angina pectoris [BA40] [15]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Cilostazol. Arterial occlusive disease [BD40] [15]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Posaconazole. Aspergillosis [1F20] [15]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Levalbuterol. Asthma [CA23] [23]
Terbutaline DMD4381 Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Terbutaline. Asthma [CA23] [24]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Pirbuterol. Asthma [CA23] [24]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Salbutamol. Asthma [CA23] [23]
Formoterol DMSOURV Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Formoterol. Asthma [CA23] [24]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [16]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Desipramine. Attention deficit hyperactivity disorder [6A05] [19]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Ofloxacin. Bacterial infection [1A00-1C4Z] [25]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Clarithromycin. Bacterial infection [1A00-1C4Z] [15]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Hydroxyzine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [15]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [25]
Linezolid DMGFPU2 Moderate Additive CNS depression effects by the combination of Hydroxyzine and Linezolid. Bacterial infection [1A00-1C4Z] [15]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [25]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Norfloxacin. Bacterial infection [1A00-1C4Z] [25]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Levofloxacin. Bacterial infection [1A00-1C4Z] [25]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [15]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Telithromycin. Bacterial infection [1A00-1C4Z] [15]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Cariprazine. Bipolar disorder [6A60] [19]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Hydroxyzine and Loperamide. Bowel habit change [ME05] [26]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Eribulin. Breast cancer [2C60-2C6Y] [15]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Lapatinib. Breast cancer [2C60-2C6Y] [15]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Tamoxifen. Breast cancer [2C60-2C6Y] [15]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Bosutinib. Breast cancer [2C60-2C6Y] [16]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Hydroxyzine when combined with Acetylcholine. Cataract [9B10] [27]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [28]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [29]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [24]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [23]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [29]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [24]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [29]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [24]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [24]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Hydroxyzine and Dihydrocodeine. Chronic pain [MG30] [30]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Isoproterenol. Conduction disorder [BC63] [23]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Hydroxyzine and Olopatadine. Conjunctiva disorder [9A60] [31]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Halothane. Corneal disease [9A76-9A78] [15]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Propofol. Corneal disease [9A76-9A78] [32]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Sevoflurane. Corneal disease [9A76-9A78] [15]
Alfentanil DMVO0UB Major Additive CNS depression effects by the combination of Hydroxyzine and Alfentanil. Corneal disease [9A76-9A78] [18]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Hydroxyzine and Remifentanil. Corneal disease [9A76-9A78] [18]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Probucol. Coronary atherosclerosis [BA80] [15]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Clofazimine. Crohn disease [DD70] [33]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Mifepristone. Cushing syndrome [5A70] [15]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Pasireotide. Cushing syndrome [5A70] [15]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Osilodrostat. Cushing syndrome [5A70] [16]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Hydroxyzine and Ethanol. Cystitis [GC00] [31]
Trimipramine DM1SC8M Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Trimipramine. Depression [6A70-6A7Z] [19]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Cyclobenzaprine. Depression [6A70-6A7Z] [19]
Isocarboxazid DMAF1NB Moderate Additive CNS depression effects by the combination of Hydroxyzine and Isocarboxazid. Depression [6A70-6A7Z] [15]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Escitalopram. Depression [6A70-6A7Z] [15]
Tranylcypromine DMGB5RE Moderate Additive CNS depression effects by the combination of Hydroxyzine and Tranylcypromine. Depression [6A70-6A7Z] [15]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Hydroxyzine and OPC-34712. Depression [6A70-6A7Z] [19]
Phenelzine DMHIDUE Moderate Additive CNS depression effects by the combination of Hydroxyzine and Phenelzine. Depression [6A70-6A7Z] [15]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Clomipramine. Depression [6A70-6A7Z] [19]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Trazodone. Depression [6A70-6A7Z] [34]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Doxepin. Depression [6A70-6A7Z] [19]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Maprotiline. Depression [6A70-6A7Z] [19]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Hydroxyzine and Esketamine. Depression [6A70-6A7Z] [22]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Mepenzolate. Digestive system disease [DE2Z] [19]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Oxybutynine. Discovery agent [N.A.] [19]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [15]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Meclizine. Dizziness and giddiness [MB48] [19]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Ingrezza. Dystonic disorder [8A02] [35]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Hydroxyzine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [36]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Diphenhydramine. Episodic vestibular syndrome [AB31] [19]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Solifenacin. Functional bladder disorder [GC50] [19]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Tolterodine. Functional bladder disorder [GC50] [19]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Pentamidine. Fungal infection [1F29-1F2F] [15]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Ketoconazole. Fungal infection [1F29-1F2F] [15]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Propantheline. Gastric ulcer [DA60] [19]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Cisapride. Gastro-oesophageal reflux disease [DA22] [15]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [15]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Hydroxyzine when combined with Isoflurophate. Glaucoma [9C61] [27]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Hydroxyzine when combined with Pilocarpine. Glaucoma [9C61] [27]
Procarbazine DMIK367 Moderate Additive CNS depression effects by the combination of Hydroxyzine and Procarbazine. Hodgkin lymphoma [2B30] [15]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [37]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [38]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [39]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [15]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Belladonna. Infectious gastroenteritis/colitis [1A40] [19]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Amantadine. Influenza [1E30-1E32] [40]
Propiomazine DMKY8V1 Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Propiomazine. Insomnia [7A00-7A0Z] [19]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Hydroxyzine and ITI-007. Insomnia [7A00-7A0Z] [19]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Polyethylene glycol. Irritable bowel syndrome [DD91] [16]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Phenolphthalein. Irritable bowel syndrome [DD91] [15]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Clidinium. Irritable bowel syndrome [DD91] [19]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Dicyclomine. Irritable bowel syndrome [DD91] [19]
Physostigmine DM2N0TO Moderate Antagonize the effect of Hydroxyzine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [21]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Crizotinib. Lung cancer [2C25] [41]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Ceritinib. Lung cancer [2C25] [15]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Osimertinib. Lung cancer [2C25] [42]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Selpercatinib. Lung cancer [2C25] [16]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Lumefantrine. Malaria [1F40-1F45] [22]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Halofantrine. Malaria [1F40-1F45] [43]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Chloroquine. Malaria [1F40-1F45] [44]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Hydroxychloroquine. Malaria [1F40-1F45] [44]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Primaquine. Malaria [1F40-1F45] [15]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [16]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [45]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Vemurafenib. Melanoma [2C30] [15]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and LGX818. Melanoma [2C30] [46]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Hydroxyzine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [47]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Hydroxyzine and Lasmiditan. Migraine [8A80] [48]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Hydroxyzine and Flibanserin. Mood disorder [6A60-6E23] [49]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Panobinostat. Multiple myeloma [2A83] [50]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Hydroxyzine and Thalidomide. Multiple myeloma [2A83] [51]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Siponimod. Multiple sclerosis [8A40] [22]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Fingolimod. Multiple sclerosis [8A40] [15]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Ozanimod. Multiple sclerosis [8A40] [52]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Romidepsin. Mycosis fungoides [2B01] [15]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Nilotinib. Myeloproliferative neoplasm [2A20] [15]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Dasatinib. Myeloproliferative neoplasm [2A20] [53]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Phenindamine. Nasopharyngitis [CA00] [19]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Dimenhydrinate. Nausea/vomiting [MD90] [19]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Promethazine. Nausea/vomiting [MD90] [19]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Cyclizine. Nausea/vomiting [MD90] [19]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Granisetron. Nausea/vomiting [MD90] [15]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Dolasetron. Nausea/vomiting [MD90] [15]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Ondansetron. Nausea/vomiting [MD90] [15]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Entrectinib. Non-small cell lung cancer [2C25] [22]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Levomethadyl Acetate. Opioid use disorder [6C43] [16]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Lofexidine. Opioid use disorder [6C43] [15]
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Hydroxyzine and Pentazocine. Pain [MG30-MG3Z] [18]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Hydroxyzine and Dextropropoxyphene. Pain [MG30-MG3Z] [54]
Butorphanol DM5KYPJ Major Additive CNS depression effects by the combination of Hydroxyzine and Butorphanol. Pain [MG30-MG3Z] [18]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Hydroxyzine and Oxymorphone. Pain [MG30-MG3Z] [18]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Hydroxyzine and Levorphanol. Pain [MG30-MG3Z] [18]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Hydroxyzine and Dezocine. Pain [MG30-MG3Z] [18]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Flavoxate. Pain [MG30-MG3Z] [19]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Hydroxyzine and Nalbuphine. Pain [MG30-MG3Z] [18]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Hydroxyzine and Buprenorphine. Pain [MG30-MG3Z] [55]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Hydroxyzine and Hydrocodone. Pain [MG30-MG3Z] [18]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Triclabendazole. Parasitic worm infestation [1F90] [15]
Biperiden DME78OA Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Biperiden. Parkinsonism [8A00] [19]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Pimavanserin. Parkinsonism [8A00] [56]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Orphenadrine. Parkinsonism [8A00] [19]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Apomorphine. Parkinsonism [8A00] [15]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Methylscopolamine. Peptic ulcer [DA61] [19]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Famotidine. Peptic ulcer [DA61] [22]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Macimorelin. Pituitary gland disorder [5A60-5A61] [57]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Lefamulin. Pneumonia [CA40] [58]
Ritodrine DM4V6RL Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Ritodrine. Preterm labour/delivery [JB00] [24]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Degarelix. Prostate cancer [2C82] [16]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and ABIRATERONE. Prostate cancer [2C82] [16]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Nilutamide. Prostate cancer [2C82] [16]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Enzalutamide. Prostate cancer [2C82] [16]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Relugolix. Prostate cancer [2C82] [16]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Bicalutamide. Prostate cancer [2C82] [16]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Levomepromazine. Psychotic disorder [6A20-6A25] [19]
Fluphenazine DMIT8LX Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Fluphenazine. Psychotic disorder [6A20-6A25] [19]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [59]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Quetiapine. Schizophrenia [6A20] [15]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Mesoridazine. Schizophrenia [6A20] [15]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Thioridazine. Schizophrenia [6A20] [15]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Aripiprazole. Schizophrenia [6A20] [19]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Iloperidone. Schizophrenia [6A20] [15]
Paliperidone DM7NPJS Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Paliperidone. Schizophrenia [6A20] [19]
Perphenazine DMA4MRX Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Perphenazine. Schizophrenia [6A20] [19]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Molindone. Schizophrenia [6A20] [19]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Thiothixene. Schizophrenia [6A20] [19]
Trifluoperazine DMKBYWI Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Trifluoperazine. Schizophrenia [6A20] [19]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Risperidone. Schizophrenia [6A20] [19]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Amisulpride. Schizophrenia [6A20] [60]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Asenapine. Schizophrenia [6A20] [15]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Pimozide. Schizophrenia [6A20] [16]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Hydroxyzine and Fentanyl. Sensation disturbance [MB40] [18]
Sufentanil DMU7YEL Major Additive CNS depression effects by the combination of Hydroxyzine and Sufentanil. Sensation disturbance [MB40] [18]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Vardenafil. Sexual dysfunction [HA00-HA01] [15]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Hydroxyzine and LEE011. Solid tumour/cancer [2A00-2F9Z] [15]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [15]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [16]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [15]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [15]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Hydroxyzine and Adenosine. Supraventricular tachyarrhythmia [BC81] [15]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Lenvatinib. Thyroid cancer [2D10] [15]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Cabozantinib. Thyroid cancer [2D10] [16]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Papaverine. Tonus and reflex abnormality [MB47] [61]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Hydroxyzine and Tizanidine. Tonus and reflex abnormality [MB47] [62]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Tacrolimus. Transplant rejection [NE84] [15]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Atropine. Unspecific substance harmful effect [NE6Z] [19]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Astemizole. Vasomotor/allergic rhinitis [CA08] [15]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [19]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [19]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [19]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [20]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [19]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [19]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Hydroxyzine and Azatadine. Vasomotor/allergic rhinitis [CA08] [19]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Procainamide. Ventricular tachyarrhythmia [BC71] [15]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Propafenone. Ventricular tachyarrhythmia [BC71] [15]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Hydroxyzine and Flecainide. Ventricular tachyarrhythmia [BC71] [15]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Hydroxyzine and Amiodarone. Ventricular tachyarrhythmia [BC71] [15]
⏷ Show the Full List of 213 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
D&C red no. 33 E00261 19116 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Glyceryl monostearate E00310 24699 Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Hydrazine yellow E00409 164825 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium hydrogenphosphate E00294 24441 Diluent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Ferrous oxide E00241 14945 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Water E00035 962 Solvent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 36 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Hydroxyzine 100 mg capsule 100 mg Oral Capsule Oral
Hydroxyzine 50 mg capsule 50 mg Oral Capsule Oral
Hydroxyzine 25 mg capsule 25 mg Oral Capsule Oral
Hydroxyzine Hydrochloride 10mg tablet 10mg Tablet Oral
Hydroxyzine Hydrochloride 50mg tablet 50mg Tablet Oral
Hydroxyzine Hydrochloride 25mg tablet 25mg Tablet Oral
Hydroxyzine 25 mg tablet 25 mg Oral Tablet Oral
Hydroxyzine 50 mg tablet 50 mg Oral Tablet Oral
Hydroxyzine 10 mg tablet 10 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Hydroxyzine FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7199).
3 Rayner-Hartley E, Sedlak T: Ranolazine: A Contemporary Review. J Am Heart Assoc. 2016 Mar 15;5(3):e003196. doi: 10.1161/JAHA.116.003196.
4 BDDCS applied to over 900 drugs
5 Paton DM, Webster DR: Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet. 1985 Nov-Dec;10(6):477-97.
6 Simons KJ, Watson WT, Chen XY, Simons FE: Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly. Clin Pharmacol Ther. 1989 Jan;45(1):9-14. doi: 10.1038/clpt.1989.2.
7 Understanding the pharmacokinetics of anxiolytic drugs. Expert Opin Drug Metab Toxicol. 2013 Apr;9(4):423-40. doi: 10.1517/17425255.2013.759209. Epub 2013 Jan 21.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient ... J Pharmacol Sci. 2008 Dec;108(4):462-71.
10 Product characteristics of HYDROXYZINE (Hydroxyzine Hydrochloride Capsules).
11 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
12 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
13 Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
14 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
15 Canadian Pharmacists Association.
16 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
18 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
19 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
20 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
21 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
22 Cerner Multum, Inc. "Australian Product Information.".
23 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
24 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
25 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
26 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
27 Multum Information Services, Inc. Expert Review Panel.
28 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
29 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
30 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
31 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
32 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
33 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
34 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
35 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
36 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
37 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
38 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
39 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
40 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
41 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
42 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
43 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
44 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
45 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
46 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
47 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
48 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
49 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
50 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
51 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
52 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
53 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
54 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
55 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
56 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
57 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
58 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
59 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
60 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
61 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
62 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.